CERRI, Stefania
 Distribuzione geografica
Continente #
NA - Nord America 12.553
EU - Europa 9.659
AS - Asia 2.597
SA - Sud America 233
AF - Africa 27
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 11
Totale 25.098
Nazione #
US - Stati Uniti d'America 12.482
IT - Italia 4.860
GB - Regno Unito 1.957
SG - Singapore 805
SE - Svezia 705
CN - Cina 685
DE - Germania 533
HK - Hong Kong 429
RU - Federazione Russa 328
FR - Francia 302
UA - Ucraina 270
FI - Finlandia 207
TR - Turchia 200
BR - Brasile 181
ID - Indonesia 137
BG - Bulgaria 125
NL - Olanda 91
IN - India 68
JP - Giappone 65
IE - Irlanda 59
CA - Canada 45
VN - Vietnam 45
BE - Belgio 44
KR - Corea 41
RO - Romania 32
ES - Italia 26
PK - Pakistan 23
MX - Messico 21
LT - Lituania 17
IR - Iran 16
TW - Taiwan 15
CH - Svizzera 14
AR - Argentina 13
AT - Austria 13
PL - Polonia 13
MY - Malesia 11
AU - Australia 10
CO - Colombia 9
CZ - Repubblica Ceca 9
EG - Egitto 9
AL - Albania 8
CL - Cile 8
EU - Europa 8
JO - Giordania 8
NZ - Nuova Zelanda 8
ZA - Sudafrica 8
LV - Lettonia 7
SA - Arabia Saudita 7
VE - Venezuela 7
IQ - Iraq 6
PE - Perù 6
TN - Tunisia 6
UZ - Uzbekistan 6
DK - Danimarca 5
GR - Grecia 5
NO - Norvegia 5
AZ - Azerbaigian 4
EC - Ecuador 4
HR - Croazia 4
IL - Israele 4
KG - Kirghizistan 4
LU - Lussemburgo 4
RS - Serbia 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
BZ - Belize 3
HU - Ungheria 3
MA - Marocco 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BD - Bangladesh 2
EE - Estonia 2
KZ - Kazakistan 2
PT - Portogallo 2
A1 - Anonimo 1
AD - Andorra 1
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
JM - Giamaica 1
KE - Kenya 1
MM - Myanmar 1
OM - Oman 1
PH - Filippine 1
PY - Paraguay 1
SI - Slovenia 1
SM - San Marino 1
TM - Turkmenistan 1
VA - Santa Sede (Città del Vaticano) 1
Totale 25.098
Città #
Fairfield 1.687
Southend 1.635
Santa Clara 1.621
Woodbridge 987
Ashburn 947
Chandler 947
Houston 735
Seattle 605
Wilmington 532
Singapore 526
Cambridge 515
Dearborn 469
Ann Arbor 444
Nyköping 444
Jacksonville 424
Hong Kong 417
Milan 326
Rome 300
Modena 204
Beijing 179
San Diego 173
New York 142
Helsinki 135
Jakarta 130
Princeton 123
Sofia 123
Naples 110
Eugene 105
Florence 95
Palermo 93
Izmir 91
Moscow 88
Bologna 86
Redwood City 83
Bari 67
London 65
Catania 59
Bremen 56
Shanghai 53
Turin 51
Tokyo 49
Boardman 46
Brussels 37
Munich 37
Dong Ket 36
Dublin 36
Genoa 36
Reggio Emilia 36
Padova 35
Phoenix 35
Verona 30
Guangzhou 28
Cagliari 27
Falls Church 26
Mountain View 26
Norwalk 26
Parma 26
Frankfurt am Main 24
São Paulo 24
Grafing 22
Salerno 21
Timisoara 21
Chicago 20
Los Angeles 20
Brescia 19
Pescara 18
Venice 18
Bergamo 17
Hefei 17
Ottawa 17
San Francisco 17
San Jose 17
Lahore 16
Nanjing 16
Treviso 16
Monza 15
Perugia 15
Trieste 15
Jinan 14
Messina 14
Berlin 13
Chiswick 13
Ankara 12
Leawood 12
Paris 12
Saint Petersburg 12
Toronto 12
Cinisello Balsamo 11
Kilburn 11
Nuremberg 11
Pisa 11
Rimini 11
Torino 11
Kunming 10
Livorno 10
Menlo Park 10
Napoli 10
Reggio Calabria 10
Reggio Nell'emilia 10
Siena 10
Totale 17.079
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.308
Malattie infiltrative diffuse del polmone 901
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 695
Non-steroid agents for idiopathic pulmonary fibrosis 301
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 294
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 282
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 281
Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease 263
Effectiveness of pulmonary rehabilitation in patients with INTERSTITIAL LUNG DISEASE of different etiology: a multicenter prospective study 259
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 256
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 246
Acute exacerbation of Idiopathic Pulmonary Fibrosis: lessons learned from the Acute Respiratory Distress Syndrome 245
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 238
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. 238
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 238
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 238
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 231
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 228
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 227
Rifabutin for treating pulmonary tuberculosis. 222
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 220
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 214
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 214
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 210
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 209
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 209
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 206
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 204
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 203
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 200
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 199
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 199
Pulmonary fibrosis and the many faces of UIP 198
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis. 198
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 197
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 195
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 194
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 191
The encaged lung: rapidly progressive idiopathic pleurisy. 189
Ultrasound assessed Diaphragm Impairment is a Predictor of Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease undergoing Non-Invasive Ventilation. 188
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 187
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 185
Janus-faced amiodarone-induced pneumopathy 185
Management of Idiopathic Pulmonary Fibrosis 183
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 182
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 182
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 182
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 181
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 181
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 180
Sarcoidosis: challenging diagnostic aspects of an old disease. 179
Smoking-related interstitial lung disease 179
Serial Ultrasound Assessment of Diaphragmatic Function and Clinical Outcome in Patients with Amyotrophic Lateral Sclerosis. 179
Proteomics Analysis of Formalin-Fixed Paraffine-Embedded Tissue Reveals Key Proteins Related to Lung Dysfunction in Idiopathic Pulmonary Fibrosis. 177
Management of idiopathic pulmonary fibrosis. 177
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease 175
Emerging drugs for idiopathic pulmonary fibrosis. 174
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 173
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation 172
The big clinical trials in idiopathic pulmonary fibrosis. 171
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 171
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 165
Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? 165
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 165
Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment. 165
Human mucosal associated invariant T cells detect bacterially infected cells 164
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 163
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 161
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 159
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 159
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 159
Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. 159
Genetic testing in diffuse parenchymal lung disease 158
Tubercolosi 153
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 153
Morbidity and Mortality in Patients with Idiopathic Pulmonary Fibrosis Undergoing Diagnostic Surgical Lung Biopsy 151
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 150
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 149
Challenges in idiopathic interstitial lung disease 146
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 146
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 146
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 145
Pulmonary stretch and lung mechanotransduction: Implications for progression in the fibrotic lung 145
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice 143
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 140
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 140
Unusual effectiveness of systemic steroids in Whipple disease. 140
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 136
Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. 134
Predictive Value of DLCO Reduction in Scleroderma Patients Without Cardio-Pulmonary Involvement at Baseline 133
Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming? 133
Do not forget to assess the muscle integrity in COPD patients. 132
Sindrome di Goodpasture 131
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? 130
Inspiratory effort and respiratory mechanics in spontaneously breathing patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective matched control study. 130
Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases 128
Pneumologia 127
Infezioni sistemiche a prevalente localizzazione polmonare 125
Human IL-10 Producing T Cells Specific for Mycobacterium tuberculosis. 124
Tubercolosi 120
Totale 22.655
Categoria #
all - tutte 92.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.090


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.565 0 0 0 0 0 0 0 456 440 229 264 176
2020/20213.590 362 191 267 312 361 311 320 362 211 404 264 225
2021/20222.947 229 293 156 210 142 187 146 156 332 226 495 375
2022/20233.613 349 340 237 313 360 424 166 381 428 144 260 211
2023/20243.644 172 201 235 342 471 373 470 407 127 145 305 396
2024/20254.497 315 177 223 506 1.361 990 674 251 0 0 0 0
Totale 25.424